Upgrade to SI Premium - Free Trial

Eli Lilly & Co. (LLY) Tops Q2 EPS by 16c; Updates FY15 Outlook

July 23, 2015 6:26 AM

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $0.90, $0.16 better than the analyst estimate of $0.74. Revenue for the quarter came in at $4.98 billion versus the consensus estimate of $4.89 billion.

The following table summarizes the company's 2015 financial guidance:

2015 Guidance

Prior

Revised

Revenue

$19.5 to $20.0 billion

$19.7 to $20.0 billion

Gross Margin % of Revenue (reported)

Approx. 74.5%

Approx. 74.5%

Gross Margin % of Revenue (non-GAAP)

Approx. 78.0%

Approx. 78.0%

Marketing, Selling & Admin (reported)

$6.4 to $6.7 billion

$6.4 to $6.7 billion

Marketing, Selling & Admin (non-GAAP)

$6.3 to $6.6 billion

$6.3 to $6.6 billion

Research & Development

$4.7 to $4.9 billion

$4.7 to $4.9 billion

Other Income/(Expense) (reported)

$75 to $125 million

($50 million) to $0

Other Income/(Expense) (non-GAAP)

$75 to $125 million

$100 to $150 million

Tax Rate (reported)

Approx. 16.5%

Approx. 14.5%

Tax Rate (non-GAAP)

Approx. 21.5%

Approx. 21.0%

Earnings per share (reported)

$2.21 to $2.31

$2.20 to $2.30

Earnings per share (non-GAAP)

$3.10 to $3.20

$3.20 to $3.30

Capital Expenditures

Approx. $1.3 billion

Approx. $1.3 billion

*** The Street sees FY15 revenue of $19.80 billion and EPS of $3.18.

The company's 2015 financial guidance is subject to final acquisition accounting adjustments for the acquisitions of Novartis Animal Health and Erbitux rights.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

Categories

Earnings Guidance Hot Earnings Hot Guidance

Next Articles